- Roche Holding Ag
- 09 March 2026 14:46:51
Source: Sharecast
The Swiss pharma giant, which had predicted that annual sales of Giredestrant would peak at more than CHF3bn ($3.9bn), said that the persevERA breast-cancer study didn't show a statistically significant improvement in progression-free survival – though a "numerical improvement" was observed.
The trial focused on people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.
“While persevERA didn’t meet its primary objective, we are confident in the potential of giredestrant to become a new standard-of-care endocrine therapy in early and advanced ER-positive breast cancer," said Levi Garraway, Roche's chief medical office and head of global product development.
“We believe there is a path forward for combining giredestrant with a CDK4/6 inhibitor in the adjuvant setting and we are conducting further studies. The efficacy demonstrated in evERA and lidERA provides clear validation of the clinical activity of giredestrant and reinforces the strength of our expanding clinical development programme.”
The stock, which fell as much as 8% early on, was down 3.3% at CHF329.80 in afternoon trade.
